Abstract
BackgroundAsthma is the most prevalent chronic airway disease observed in children and adolescents, yet the variety of treatment options available for this age group is limited. With many factors influencing therapeutic efficacy including patient knowledge, adherence, and therapy choice as well as delivery device, it is important to have more options to tailor to individual patient needs.MethodsThis article is an overview of recent scientific articles using a systematic literature search in PubMed and specialist databases.ResultsTiotropium is the first long-acting muscarinic antagonist to be licensed for treatment of asthma and has been demonstrated to be an effective add-on therapy across all age groups. Its therapeutic success in clinical trials resulted in Food and Drug Administration and the European Medicines Agency approval for asthma treatment in people over the age of 6 years in the US and EU.ConclusionFurther studies into the use of tiotropium, especially in younger children, could be of interest for future treatment decisions.
Highlights
Asthma is a disease characterised by chronic airway inflammation and is estimated to affect over 300 million people worldwide [1, 2]
We examine the potential use of the longacting muscarinic antagonist (LAMA) tiotropium as an add-on therapy for asthma management in children and adolescents aged between 6–17 years
Post hoc analysis in adult patients with asthma demonstrated an improvement in lung function upon addition of tiotropium to maintenance therapy across Global Initiative for Asthma (GINA) Steps 2–5 [46]. These analyses indicate that tiotropium can be used as an additional controller therapy to inhaled corticosteroids (ICS) in a wide range of patients with asthma
Summary
Tiotropium is the first long-acting muscarinic antagonist to be licensed for treatment of asthma and has been demonstrated to be an effective add-on therapy across all age groups. Its therapeutic success in clinical trials resulted in Food and Drug Administration and the European Medicines Agency approval for asthma treatment in people over the age of 6 years in the US and EU
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
